Around 13,000 people are diagnosed with a primary brain tumour in the UK each year, and brain tumours are the leading cause of cancer death in children and adults under 40.
Glioblastoma (GBM), the most common malignant primary brain tumour in adults, is highly aggressive and infiltrative. It has a poor prognosis and can profoundly affect cognition, communication, mobility and independence, placing a significant burden on patients and families.
Addressing this disease burden requires treatment innovation and a clear pathway from research through assessment, funding and adoption so that promising treatments can reach the patients who may benefit from them.
Over the past two decades, there have been important advances in the diagnosis and management of GBM. Advances in genetic and biological testing are helping clinicians understand the individual characteristics of a tumour and make more informed treatment decisions, while improved imaging and surgical techniques allow surgeons to remove tumours more precisely while protecting healthy brain tissue.
However, while innovation has brought new approaches to treating brain tumours, only some of these advances have translated into treatment options that patients can access in routine care. A renewed national focus on brain cancer offers an opportunity to turn growing scientific and policy momentum into meaningful progress for patients.
In June 2007, NICE recommended temozolomide for newly diagnosed high-grade glioma. Since then, research has produced new insights and treatment approaches, but progress in expanding the options routinely available to NHS patients with newly diagnosed GBM has been limited.
A changing policy landscape
There are, however, reasons for renewed optimism. A growing focus on brain cancer in national policy creates an opportunity to address some of the barriers between research and patient access. The Less Survivable Cancers Taskforce is an initiative which seeks to improve outcomes through greater focus on earlier diagnosis, research and access to new treatments and technologies.
The Rare Cancers Act 2026 aims to strengthen research and improve access to clinical trials for people with rare cancers, while the National Cancer Plan recognises the need to improve brain cancer outcomes, including an initial £13.7m investment in the NIHR Brain Tumour Research Consortium.
And new approaches are emerging to help promising innovations move into patient care. NICE’s early-use HealthTech guidance allows selected technologies to be used in the NHS while further evidence is generated, and the National HealthTech Access Programme aims to support faster, more consistent national access to selected high-impact technologies. These are an opportunity to create a more connected pathway for clinically effective innovations to be assessed, funded and adopted.
The importance of creating such a pathway becomes clearer when considering the continuing pace of scientific innovation in GBM. Targeted therapies, vaccines, immunotherapies, novel drug-delivery techniques and device-based treatments are at varying stages of development and adoption.
Tumour Treating Fields (TTFields), which use alternating electric fields to disrupt cancer cell division, are one modality that is approved by health regulators and used to treat newly diagnosed GBM in several healthcare systems, including the US, Germany, France, Sweden and Spain. TTFields are not routinely available to NHS patients.
Building a pathway from evidence to adoption
The challenge is therefore not simply to develop new approaches to treating GBM but to ensure that those demonstrating meaningful clinical benefit can reach patients. For new treatments in rare, aggressive cancers, three areas require particular attention:
– When an innovation demonstrates meaningful clinical benefit, there should be a route to national assessment that reflects the urgency of unmet need and the realities of generating evidence in small patient populations.
– Rigorous evaluation must remain the standard, but some uncertainty may be unavoidable in rare, aggressive diseases. Where appropriate, mechanisms for further evidence generation can help manage this uncertainty while supporting informed decisions about patient access.
– Researchers, innovators, regulators, assessment bodies, clinicians, commissioners and patients should engage earlier to align evidence requirements, trial design and implementation planning, allowing potential barriers to evaluation, funding and adoption to be identified before clinical development is complete.
Evidence generation and assessment alone cannot secure patient access; funding, commissioning and implementation must also be aligned to support equitable adoption across the NHS.
Other health systems are exploring more integrated approaches. Ontario’s Health Innovation Pathway brings evidence assessment together with implementation planning that considers clinical, policy, funding and supply-chain requirements, creating a roadmap towards wider adoption. Although its institutional context differs from the UK NHS, the model illustrates the value of treating evidence, assessment, funding and implementation as a coherent pathway rather than a succession of separate hurdles.
Investment in research offers hope that the next generation of treatments will deliver better outcomes for people with GBM. Realising the ambitions of the National Cancer Plan and wider commitments to rare and less survivable cancers will require policymakers, clinicians, researchers and health system leaders to look beyond innovation itself and ask what needs to change for effective new treatments to reach patients.
For people living with aggressive brain tumours, meaningful progress means more treatment options, better outcomes and ultimately more precious time with family, friends and loved ones.
Discover how Novocure is advancing innovation in cancer care: https://www.novocure.co.uk/



